![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting |
Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, Keon Uk Park, Ho Jung An, Joohyuk Sohn, Young Mi Seol, Hyunwoo Lee, Hwan-Jung Yun, Jin Seok Ahn, Ji Hyun Yang, Hunho Song, Dong-Hoe Koo, Jin Young Kim, Gun Min Kim, Hwa Jung Kim |
Cancer Research and Treatment. 2020;52(3):907-916. Published online 2020 March 18 DOI: https://doi.org/10.4143/crt.2019.713 |
1287 POSTER Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy-induced nausea & vomiting after emetogenic chemotherapy Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting The Efficacy of Triplet Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving Highly Emetogenic Chemotherapy: Palonosetron (PALO), Aprepitant (APR), and Dexamethasone (DEX) PCN22 COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy 342P Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer 3072 Palonosetron plus a three-day aprepitant and dexamethasone schedule to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy |
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014. |